glp-1 agonist and gastroparesis Drugs Gastroparesis: What Patients Should Know? ❗ 𝐀 𝐦𝐮𝐬𝐭 𝐫𝐞𝐚𝐝 𝐩𝐚𝐩𝐞𝐫:

This review examines their expanding role, evaluating efficacy compared to alternative treatments, ...

This analysis of survey data finds that over 40% of adults under 65 with private insurance could be indicated for a GLP-1 drug though relatively few have a claim, suggesting that a much smaller share seeks treatment through healthcare providers.

A massive study of veterans suggests these medications may quiet cravings far beyond food.

Despite their exploding popularity, the current GLP-1 injections (semaglutide though is also orally available) face accessibility issues due to cost and adverse effects and thus the next big move for the space, an easy to - pop pill could be lucrative, for which clinical trials are already well underway

The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes

Here, we aimed to provide an overview of retatrutide's safety and effectiveness in treating obesity.